Safety of bisphosphonates.

Safety of bisphosphonates.

Bisphosphonates are one of the most well studied groups of medications and they are bone specific. This tissue specificity is a rare property for a drug introduced into clinical practice as long as 40 years ago. Over the years, the therapeutic boundaries of bisphosphonates were explored and their sa...

Bibliografske podrobnosti
Main Authors:	Pazianas, M, Abrahamsen, B
Format:	Journal article
Jezik:	English
Izdano:	2011

Podobne knjige/članki

Safety issues with bisphosphonate therapy for osteoporosis.
od: Suresh, E, et al.
Izdano: (2014)

Comment on Tadrous et al.: comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis.
od: Pazianas, M, et al.
Izdano: (2014)

Eliminating the need for fasting with oral administration of bisphosphonates.
od: Pazianas, M, et al.
Izdano: (2013)

Bisphosphonates and colon cancer: reply.
od: Pazianas, M, et al.
Izdano: (2013)

Bisphosphonates and colon cancer: Reply
od: Pazianas, M, et al.
Izdano: (2013)

Findings of Danish study on risk of colon cancer in bisphosphonate users were misinterpreted.
od: Abrahamsen, B, et al.
Izdano: (2013)

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.
od: Pazianas, M, et al.
Izdano: (2010)

Evaluating the antifracture efficacy of bisphosphonates.
od: Pazianas, M, et al.
Izdano: (2009)

Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study.
od: Pazianas, M, et al.
Izdano: (2012)

Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: cohort analysis using a national prescription database.
od: Pazianas, M, et al.
Izdano: (2013)

Bisphosphonates and bone quality.
od: Pazianas, M, et al.
Izdano: (2014)

Atrial fibrillation and bisphosphonate therapy.
od: Pazianas, M, et al.
Izdano: (2010)

Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
od: Pazianas, M, et al.
Izdano: (2012)

Potential therapeutic effects of oral bisphosphonates on the intestine.
od: Pazianas, M, et al.
Izdano: (2011)

Are bisphosphonates associated with an increased risk of atypical femoral fractures as a class?
od: Pazianas, M
Izdano: (2013)

NE‐58025: A bisphosphonate with a low hydroxyapatite binding affinity
od: Michael Pazianas
Izdano: (2021-08-01)

Atrial fibrillation and the use of oral bisphosphonates
od: Michael Pazianas, et al.
Izdano: (2011-03-01)

Atrial fibrillation and the use of oral bisphosphonates.
od: Pazianas, M, et al.
Izdano: (2011)

Oral bisphosphonates and chronic kidney disease: progression and safety
od: Prieto-Alhambra, D, et al.
Izdano: (2018)

NO ASSOCIATION BETWEEN THE USE OF ORAL BISPHOSPHONATES AND INCIDENCE OF ATRIAL FIBRILLATION
od: Pazianas, M, et al.
Izdano: (2010)

Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker.
od: Pazianas, M, et al.
Izdano: (2008)

Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker: Reply to Yarom and Elad
od: Pazianas, M, et al.
Izdano: (2008)

A NEPHROLOGIST’S VIEW TO RENAL SAFETY OF BISPHOSPHONATES
od: Sevgi Şahin
Izdano: (2007-07-01)

Patients With atypical femur fractures have the same mortality as the background population--drug-dhanneling bias, bisphosphonate effects, and public health implications
od: Abrahamsen, B, et al.
Izdano: (2016)

BISPHOSPHONATE USE AND IMPROVED IMPLANT SURVIVAL: A NATIONWIDE COHORT STUDY
od: Alhambra, D, et al.
Izdano: (2013)

Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a binational cohort analysis
od: Robinson, DE, et al.
Izdano: (2021)

Safety and efficacy of bisphosphonates in thalassemia patients with osteopenia/osteoporosis
od: Sujata Sharma, et al.
Izdano: (2023-04-01)

A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
od: Pazianas, M, et al.
Izdano: (2007)

Bisphosphonates
od: Bishop, N, et al.
Izdano: (2013)

Bisphosphonates
od: Fırat Öztürk
Izdano: (2009-04-01)

Impact of bisphosphonates in age-related macular degeneration: Retrospective cohort and nested case-control study
od: Garriga, C, et al.
Izdano: (2018)

BISPHOSPHONATE USE AND IMPROVED IMPLANT SURVIVAL: A NATION-WIDE COHORT STUDY
od: Prieto-Alhambra, D, et al.
Izdano: (2013)

Oral bisphosphonate use and age-related macular degeneration: retrospective cohort and nested case-control study
od: Garriga, C, et al.
Izdano: (2018)

Impact of bisphosphonate use and age-related macular degeneration: retrospective cohort and nested case-control study
od: Garriga, C, et al.
Izdano: (2018)

Bisphosphonates and Age-Related Macular Degeneration: A Propensity-Matched Cohort and Nested Case-Control Analysis
od: Garriga, C, et al.
Izdano: (2017)

Bisphosphonates 2006
od: Russell, R
Izdano: (2006)

Oral bisphosphonate use reduces cardiovascular events in a cohort of Danish patients referred for bone mineral density
od: Rodriguez, AJ, et al.
Izdano: (2020)

Bisphosphonates: Mechanisms of Action
od: Roelofs, A, et al.
Izdano: (2008)

Predictors of second fracture while on treatment with oral bisphosphonates: a multinational cohort study
od: Hawley, S, et al.
Izdano: (2014)

Oral bisphosphonate use and total knee/hip implant survival: validation of results in an external population-based cohort.
od: Prieto-Alhambra, D, et al.
Izdano: (2014)